Epigenetic Editing Explodes on the Heels of Gene Editing Success
BioSpace
MARCH 24, 2024
Ubiquitous potential, possible safety advantages and the recent growth of cell and gene therapy are driving investment in a different type of genetic editing.
Sun.Mar 24, 2024
140 
Eisai and Biogen facing delay to Leqembi in Europe
pharmaphorum
MARCH 24, 2024
Eisai and Biogen are facing a delay in the review of their Alzheimer's therapy Leqembi in the EU, for "procedural" reasons
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Opinion: ALS Is Not a Singular Disease. Stop Treating It Like One
BioSpace
MARCH 24, 2024
Imagine testing a really good drug for HER2+ breast cancer in someone with liver cancer. Would it be any surprise when that drug fails?
Inappropriate Diagnosis of Pneumonia Among Hospitalized Adults
JAMA Internal Medicine
MARCH 24, 2024
This cohort study characterizes inappropriate diagnosis of community-acquired pneumonia among hospitalized patients in 48 Michigan hospitals.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Merck, Others Look to Immunotherapy Combos as Next Frontier in Oncology
BioSpace
MARCH 24, 2024
Drugmakers are testing a variety of biologics and small molecules in conjunction with therapies aimed at modulating the immune system to target and destroy cancer cells.
Fatal Traffic Risks With a Total Solar Eclipse in the US
JAMA Internal Medicine
MARCH 24, 2024
This case-control study describes the incidence of fatal traffic crashes in the US during the 2017 total solar eclipse.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Arkansas Law Prohibiting Manufacturer 340B Contract Pharmacy Restrictions Upheld by 8th Circuit
FDA Law Blog
MARCH 24, 2024
By Faraz Siddiqui — As drug manufacturers battle the Health Resources and Services Administration (“HRSA”) in federal courts over the role of 340B contract pharmacies, an Eighth Circuit decision to uphold a 2021 Arkansas law may render those cases inconsequential in that state. The 340B contract pharmacy dispute involves several manufacturers who are refusing to provide 340B discounts to covered entities if they requested 340B drugs to be delivered to, and dispensed from, a network of contract p
Novo’s $1.1B Cardior Buy Continues Expansion into Heart Disease
BioSpace
MARCH 24, 2024
Just weeks after Wegovy won FDA approval for cardiovascular disease, Novo Nordisk has bought mid-stage biotech Cardior Pharmaceuticals and its miRNA-targeting candidate for heart failure.
Which drugs have supplementary protection certificates in the most countries?
Drug Patent Watch
MARCH 24, 2024
This chart shows the drugs with the most supplementary protection certificates (SPCs).
Wegovy Cardiovascular Approval Furthers March into New Indications
BioSpace
MARCH 24, 2024
The recent FDA decision will likely mean more Medicare patients gain access to the blockbuster weight loss drug, experts say. Meanwhile, results continue to roll in for GLP-1 agonists for conditions beyond diabetes and obesity.
Effectiveness of an AI–Enabled Intervention for Detecting Clinical Deterioration
JAMA Internal Medicine
MARCH 24, 2024
This cohort study examines whether the use of an artificial intelligence–enabled deterioration model is associated with a decrease in the risk of escalations in care in hospitalized patients.
AbbVie Acquires Landos in Potential $212M Deal, Bolsters Anti-Inflammatory Pipeline
BioSpace
MARCH 24, 2024
Monday’s announced buyout of Virginia-based Landos Biopharma adds a mid-stage, oral NLRX1 agonist for ulcerative colitis and Crohn’s disease to AbbVie’s growing portfolio.
Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion
BioSpace
MARCH 24, 2024
Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
BioSpace
MARCH 24, 2024
Regeneron’s bispecific antibody odronextamab was hit with Complete Response Letters from the FDA noting issues with the enrollment status of its confirmatory trials.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
J&J Wins FDA Nod for Pulmonary Arterial Hypertension Combo Pill
BioSpace
MARCH 24, 2024
Johnson & Johnson’s Opsynvi has been approved by the FDA for the treatment of pulmonary arterial hypertension, combining macitentan, which cuts the risk of clinical worsening and hospitalization, while tadalafil boosts patients’ exercise capacity.
Let's personalize your content